5858 Horton Street, Suite 210
53 articles about Gritstone Oncology
Bristol-Myers Squibb and Gritstone Oncology Announce Clinical Research Collaboration to Evaluate Novel Immunotherapy Approach in Advanced Solid Tumors
Bristol-Myers Squibb Company (NYSE: BMY) and Gritstone Oncology today announced that the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Gritstone’s personalized neoantigen immunotherapy, GRANITE-001
Gritstone Oncology to Present First Data Bridging Tumor Antigen Identification and Potent Immunotherapy Delivery in Primates at 2018 AACR Annual Meeting
Gritstone Oncology announced that preclinical data highlighting the company’s tumor-specific neoantigen (TSNA) identification platform, EDGETM (Epitope Discovery in cancer GEnomes), and a novel, potent TSNA delivery approach will be presented during two poster presentations at the 2018 American Association for Cancer Research (AACR) Annual Meeting.
Gritstone Oncology Appoints Jayant Aphale, Ph.D. as Executive Vice President of Technical Operations
Senior Biopharma Executive Brings More Than 25 Years of Global Pharmaceutical Production and Supply Experience Across Vaccines, Biologics and Oligonucleotides.
Gritstone Oncology Appoints Jean-Marc Bellemin as Chief Financial Officer
Gritstone Oncology announced today the appointment of Jean-Marc Bellemin as Executive Vice President of Finance and Chief Financial Officer, effective January 5, 2018.
Gritstone Oncology is hanging a "help wanted" sign as the company looks to staff a new 43,000 square-foot manufacturing facility in Pleasanton, Calif. that will be the center of the company's immunotherapy manufacturing efforts.
Gritstone Oncology and Arbutus Biopharma Announce LNP Technology Licensing Agreement to Develop Novel RNA-Based Personalized Neoantigen Immunotherapies for Cancer Patients
Arbutus is deploying its proprietary lipid nanoparticle (LNP) technology to deliver Gritstone’s RNA-based neoantigen immunotherapy products.
Google Gets in on Bay Area Gritstone Oncology's $92.7 Million Series B Boost
Gritstone Oncology Expands Scientific Advisory Board With Appointment Of Immuno-Oncology Experts James L. Gulley And Alessandro Sette
Genentech Exec Jumps Ship to Become CMO at Gritstone Oncology
Gritstone Oncology Appoints Raphaël F. Rousseau, M.D., Ph.D., As Chief Medical Officer
First Public Data Presented From Gritstone Oncology’s Tumor Antigen Identification Platform For Personalized Cancer Immunotherapy
Immune Design Corporation And Gritstone Oncology Announce Clinical Collaboration For Neoantigen Cancer Immunotherapy
Gritstone Oncology Appoints Dr. Karin Jooss As Chief Scientific Officer